Report Phase 2 data for ANX007 in geographic atrophy
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 31 Dec 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“ANX007 (IVT) Geographic Atrophy (GA) Ph2 data”
What we found
Evidence strength A What the grades mean
The company did not report Phase 2 data for ANX007 in geographic atrophy by the end of 2021, with subsequent filings indicating the data was expected in 2023.
-
A Annexon, Inc. 10-K filed 2022-03-01
“Ongoing Phase 2 Trial in Geographic Atrophy A randomized, controlled Phase 2 trial in GA patients who are at a high risk of progression is ongoing, and we anticipate reporting data from this trial in 2023.” ✓ confirmed on the page
Market reaction: the shares moved -9.6% against the S&P 500 over the three sessions around the disclosure (28 Feb 2022 to 3 Mar 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- ANX007 geographic atrophy Phase 2 data
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Annexon, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ANNX-021513 · Corrections policy